- Ages Eligible for Study
- Genders Eligible for Study
Dyslipoproteinemia, Hypercholesterolemia, Hypertriglyceridemia, hypoalphalipoproteinemia, Atherosclerosis, Type III Hyperlipoproteinemia, and Plasma Lipoproteins
- National Heart, Lung, and Blood Institute (NHLBI)
Plasma cholesterol levels greater than 200 mg/dl or less than 120 mg/dl - includes patients
with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia,
sitosterolemia, cholesteryl ester storage disease, Erdheim chester disease, lipoprotein
lipase, hepatic lipase or apo-CII deficiency, and dysbetalipoproteinemia.
Plasma LDL-C levels greater than 130 mg/dl or less than 70 mg/dl - includes patients with
diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia,
lipoprotein lipase, hepatic lipase, or apo-CII deficiency, sitosterolemia,
dysbetalipoproteinemia, abetalipoproteinemia and hypobetalipoproteinemia.
Plasma HDL-C levels greater than 70 mg/dl or less than 25 mg/dl - includes patients with
deficiency of cholesteryl ester transfer protein, lecithin cholesterol acyltransferase,
phospholipid transfer protein, lipoprotein lipase, hepatic lipase, or apo-CII, and Tangier
Plasma triglyceride levels greater than 150 mg/dl - includes patients with deficiency of
lipoprotein lipase, hepatic lipase or apoC-II, dysbetalipoproteinemia, Type IV and Type V
Inability to provide informed consent.
Lipoproteins are particles that carry fats such as cholesterol and triglycerides through the blood stream. These particles are involved in causing blood vessel disease that can lead to conditions like hardening of the arteries (atherosclerosis) or heart attacks (myocardial infarctions). This study is designed to look closely at the factors affecting lipoproteins. Researchers plan to study patients and normal volunteers by measuring lipoprotein levels in the blood. Patients and volunteers will be placed on a balanced diet during the study. In addition, researchers plan to measure levels of various hormone and enzymes in the blood. Patients and volunteers participating in the study may be asked to undergo more specific tests in order to collect more information about lipoprotein metabolism. This study may not provide direct benefits to patients and volunteers participating in it. However, information gathered from this study may help researchers develop better skills and techniques to diagnose and treat patients with diseases of lipoprotein metabolism.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001168
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland United States
Status: RecruitingContact info For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)800-411-1222xTTY8664111010prpl@cc.nih.gov